Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 5 Completion rates for combined trial arms among regions a

From: Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

Study program

Treatment group

North America

Western Europe

Australia/South Africa

Japan

Asia

Eastern Europe/Russia

South America/Mexico

IDENTITY

Placebo

291 (76.4)EE

162 (81.4)EE

37 (80.4)

99 (90.0)EE

79 (79.8)

79 (59.4)

70 (81.4)

Semagacestat 140 mg PO

198 (50.8)

129 (60.9)

29 (53.7)

69 (64.5)

58 (60.4)

69 (48.9)

31 (37.8)

EXPEDITION

Placebo

325 (72.1)

163 (76.5)

32 (84.2)

71 (87.7)

59 (84.3)

38 (61.3)

82 (74.6)

Solanezumab 400 mg IV

303 (67.8)JP

175 (80.7)

35 (76.1)

89 (89.0)

57 (87.7)

43 (75.4)

74 (77.9)

  1. aData are presented as count (%). EE = P < 0.01 vs Eastern Europe; JP = P < 0.01 vs Japan; IV = Intravenously; PO = By mouth.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193